NCT00531934View on ClinicalTrials.gov

A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

PHASE2CompletedINTERVENTIONAL

Enrollment

147

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Doxycline

100mg po daily

DRUG

erlotinib [Tarceva]

150mg po daily

Trial Locations (24)

14076

Caen

24000

Périgueux

28018

Chartres

29200

Brest

30900

Nîmes

33076

Bordeaux

33300

Bordeaux

35033

Rennes

37044

Tours

56017

Vannes

57038

Metz

66000

Perpignan

69400

Gleizé

69495

Pierre-Bénite

71100

Chalon-sur-Saône

75116

Paris

75674

Paris

75679

Paris

76000

Rouen

83007

Draguignan

87042

Limoges

95300

Pontoise

06600

Antibes

05007

Gap

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00531934 - A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter